Kuppala Manohar Babu, Syed Sunayana Begum, Bandaru Srinivas, Varre Sreedevi, Akka Jyothy, Mundulru Hema Prasad
Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad, India.
Asian Pac J Cancer Prev. 2012;13(11):5353-61. doi: 10.7314/apjcp.2012.13.11.5353.
Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity in preclinical models. It plays pivotal roles in linking inflammatory immune responses and tumor progression and is a useful candidate in gene therapy of lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 (rhIL-18) in patients with advanced cancer concluded that rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. Some viruses can induce the secretion of IL-18 for immune evasion. The individual cytokine activity might be potentiated or inhibited by combinations of cytokines. Here we focus on combinational effects of cytokines with IL-18 in cancer progression. IL-18 is an important non-invasive marker suspected of contributing to metastasis. Serum IL-18 may a useful biological marker as independent prognostic factor of survival. In this review we cover roles of IL-18 in immune evasion, metastasis and angiogenesis, applications for chemotherapy and prognostic or diagnostic significance.
白细胞介素-18（IL-18）是一种免疫刺激细胞因子，在临床前模型中具有抗肿瘤活性。它在连接炎症免疫反应和肿瘤进展中起关键作用，是淋巴瘤或淋巴样白血病基因治疗的一个有用候选物。一项针对晚期癌症患者的重组人IL-18（rhIL-18）I期研究得出结论，rhIL-18可以以生物活性剂量安全地给予晚期癌症患者。一些病毒可诱导IL-18分泌以实现免疫逃逸。细胞因子的组合可能会增强或抑制个体细胞因子的活性。在这里，我们重点关注细胞因子与IL-18在癌症进展中的联合作用。IL-18是一种重要的非侵入性标志物，被怀疑与转移有关。血清IL-18可能作为生存的独立预后因素成为一种有用的生物学标志物。在本综述中，我们涵盖了IL-18在免疫逃逸、转移和血管生成中的作用、化疗应用以及预后或诊断意义。
